CA3196146A1 - Compounds and methods for the treatment of ocular disorders - Google Patents
Compounds and methods for the treatment of ocular disordersInfo
- Publication number
- CA3196146A1 CA3196146A1 CA3196146A CA3196146A CA3196146A1 CA 3196146 A1 CA3196146 A1 CA 3196146A1 CA 3196146 A CA3196146 A CA 3196146A CA 3196146 A CA3196146 A CA 3196146A CA 3196146 A1 CA3196146 A1 CA 3196146A1
- Authority
- CA
- Canada
- Prior art keywords
- radical
- substituted
- alkyl
- compound
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094808P | 2020-10-21 | 2020-10-21 | |
| US63/094,808 | 2020-10-21 | ||
| PCT/IB2021/000708 WO2022084739A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196146A1 true CA3196146A1 (en) | 2022-04-28 |
Family
ID=81290138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196146A Pending CA3196146A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399317A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4232034A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023546452A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230110516A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116635032A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021365530A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3196146A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL302174A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023004538A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022084739A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
| WO2024100454A2 (en) * | 2022-11-11 | 2024-05-16 | Azura Ophthalmics Ltd. | Composition and methods for improving signs and symptoms of ocular disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702984C (en) * | 2007-10-19 | 2017-04-11 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| CN102065694A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂 |
| EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
| US9463201B2 (en) * | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| WO2017055924A2 (en) * | 2015-09-28 | 2017-04-06 | M.G. Therapeutics Ltd. | Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion |
| CA3020713A1 (en) * | 2016-04-19 | 2017-10-26 | Azura Ophthalmics Ltd. | Compositions for the treatment of hyperkeratosis disorders |
| CA3057569A1 (en) * | 2017-03-29 | 2018-10-04 | Azura Ophthalmics Ltd. | Agents for increasing meibomian gland lipid secretion |
| CN110996904A (zh) * | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| US20180333357A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Nanoemulsions with anti-inflammatory activity |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| WO2019096996A1 (en) * | 2017-11-17 | 2019-05-23 | Medichem, S.A. | A process to obtain a tetrahydroisoquinoline derivative |
| WO2020212755A1 (en) * | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2021
- 2021-10-20 CN CN202180086872.2A patent/CN116635032A/zh active Pending
- 2021-10-20 IL IL302174A patent/IL302174A/en unknown
- 2021-10-20 US US18/033,055 patent/US20230399317A1/en active Pending
- 2021-10-20 WO PCT/IB2021/000708 patent/WO2022084739A1/en not_active Ceased
- 2021-10-20 AU AU2021365530A patent/AU2021365530A1/en not_active Abandoned
- 2021-10-20 EP EP21882227.8A patent/EP4232034A4/en active Pending
- 2021-10-20 MX MX2023004538A patent/MX2023004538A/es unknown
- 2021-10-20 KR KR1020237016473A patent/KR20230110516A/ko active Pending
- 2021-10-20 CA CA3196146A patent/CA3196146A1/en active Pending
- 2021-10-20 JP JP2023524274A patent/JP2023546452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232034A1 (en) | 2023-08-30 |
| CN116635032A (zh) | 2023-08-22 |
| US20230399317A1 (en) | 2023-12-14 |
| KR20230110516A (ko) | 2023-07-24 |
| IL302174A (en) | 2023-06-01 |
| AU2021365530A1 (en) | 2023-06-15 |
| AU2021365530A9 (en) | 2024-02-08 |
| JP2023546452A (ja) | 2023-11-02 |
| EP4232034A4 (en) | 2024-12-04 |
| MX2023004538A (es) | 2023-06-19 |
| WO2022084739A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11643429B2 (en) | Compounds and methods for the treatment of ocular disorders | |
| US10875845B2 (en) | Compounds and methods for the treatment of ocular disorders | |
| CA3196145A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| EP4232458A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| AU2021365530A9 (en) | Compounds and methods for the treatment of ocular disorders | |
| US20250042931A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| WO2024134272A2 (en) | Compounds and methods for the treatment of dermal and ocular disorders | |
| CA3234228A1 (en) | Compounds and methods for the treatment of dermal and ocular disorders | |
| CN116940570A (zh) | 用于治疗眼部病症的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |